Comprehensive Market Report: Global Preimplantation Genetic Testing (PGT) Market
Executive Summary
The global Preimplantation Genetic Testing (PGT) market is a sophisticated and high-growth segment within reproductive genetics and assisted reproductive technology (ART). PGT enables the screening of embryos created through in vitro fertilization (IVF) for genetic abnormalities prior to implantation, thereby increasing the chances of a successful pregnancy and the birth of a healthy child. The market, encompassing PGT for aneuploidy (PGT-A), monogenic disorders (PGT-M), and structural rearrangements (PGT-SR), was valued at an estimated USD XX billion in 2025 and is projected to reach USD YY billion by 2036, expanding at a robust Compound Annual Growth Rate (CAGR) of Z% from 2026 to 2036. This growth is propelled by increasing maternal age, declining fertility rates, rising awareness of genetic disorders, technological advancements in genomic sequencing, and expanding insurance coverage and regulatory approvals. This report provides a strategic analysis of clinical applications, technological platforms, and evolving market dynamics.
1. Segments Analysis
By Test Type (Clinical Application):
-
PGT for Aneuploidy (PGT-A): The largest and fastest-growing segment. Screens embryos for chromosomal abnormalities (e.g., trisomy 21/Down syndrome) to improve IVF success rates and reduce miscarriage risk. Primarily driven by advanced maternal age and recurrent implantation failure.
-
PGT for Monogenic Disorders (PGT-M): Tests for specific inherited single-gene disorders (e.g., Cystic Fibrosis, Huntington's disease, BRCA-related cancers). A critical service for couples with known carrier status.
-
PGT for Structural Rearrangements (PGT-SR): For couples where one partner carries a balanced chromosomal rearrangement (e.g., translocation), to identify unbalanced embryos.
-
Emerging & Adjacent Applications: Includes PGT for HLA matching (to conceive a savior sibling) and non-invasive PGT (niPGT) using spent embryo culture media, which is in early-stage clinical adoption.
By Technology Platform:
-
Next-Generation Sequencing (NGS): The dominant and gold-standard platform for PGT-A and comprehensive chromosome screening. Offers high resolution, accuracy, and the ability to detect mosaicism.
-
Fluorescence In Situ Hybridization (FISH): A legacy technology for limited chromosome screening, now largely supplanted by NGS.
-
Comparative Genomic Hybridization (CGH) & Microarray-based Platforms (aCGH, SNP array): Bridge technologies between FISH and NGS, still in use but declining.
-
Polymerase Chain Reaction (PCR)-based Methods: Remain essential for PGT-M for specific single-gene disorder testing, often in conjunction with NGS.
By End-User:
-
Fertility Clinics & IVF Centers: The primary end-users, integrating PGT services into their patient treatment pathways. May have in-house labs or partner with specialized reference labs.
-
Specialized Genetics & Reference Laboratories: Centralized labs (e.g., Natera, Reprogenetics) that receive embryo biopsy samples from multiple clinics for analysis.
-
Academic & Research Institutions: Driving innovation in new PGT methodologies and expanding the scope of testable conditions.
By Service Model:
-
Standalone PGT Services: Offered by specialized labs to partnering IVF clinics.
-
Integrated IVF+PGT Programs: Offered by large fertility chains with their own lab capabilities.
2. Key Players
The market includes specialized reproductive genetics companies, large diagnostic labs, and sequencing technology providers.
Leading Companies:
-
Illumina, Inc. (Dominant provider of NGS platforms and associated PGT reagents/software via its reproductive health portfolio)
-
Thermo Fisher Scientific Inc. (Via its Applied Biosystems and genetic analysis solutions)
-
Agilent Technologies, Inc. (Microarray and NGS solutions)
-
PerkinElmer, Inc. (Via its reproductive health and genomics business)
-
CooperSurgical, Inc. (Integrated fertility company with PGT capabilities)
-
Natera, Inc. (Leader in cell-free DNA testing; strong in PGT via its Spectrum® platform)
-
Quest Diagnostics Incorporated
-
Laboratory Corporation of America Holdings (Labcorp)
-
Myriad Genetics, Inc. (Expertise in hereditary cancer and genetics)
-
Fujifilm Holdings Corporation (Via its Irvine Scientific subsidiary - media, consumables)
-
Vitrolife AB (Fertility media and consumables, expanding into genetics)
-
Progenesis, Inc. (Progeny) (Specialized PGT and genetics software)
-
Igenomix (Specialized reproductive genetics lab)
-
Reprogenetics (A leading PGT lab)
3. Regional Analysis
-
North America: The largest and most mature market, particularly the United States. Driven by high IVF utilization, favorable insurance coverage trends, advanced healthcare infrastructure, and a proactive patient population. Regulatory oversight by the FDA and CAP/CLIA ensures quality.
-
Europe: A significant market with varying regulations and reimbursement across countries. The UK, Spain, Germany, and Italy have well-established ART and PGT markets. Growth is tempered by more restrictive regulations in some countries (e.g., Germany on embryo selection).
-
Asia-Pacific: The fastest-growing regional market. Led by China, Japan, India, and Australia. Growth is fueled by rising infertility rates, improving healthcare access, growing medical tourism for IVF, and increasing disposable income. China represents a massive potential market with growing domestic capabilities.
-
Latin America, Middle East & Africa: Emerging markets with growth concentrated in urban centers and countries with more progressive regulations (e.g., Brazil, South Africa, UAE). Growth is driven by rising awareness and the presence of private fertility clinics catering to high-income populations.
4. Porter’s Five Forces Analysis
-
Competitive Rivalry (High): Competition is intense among specialized PGT labs (Natera, Reprogenetics, Igenomix) and large diagnostic companies (Labcorp, Quest) expanding into reproductive health. Competition is based on test accuracy, turnaround time, pricing, clinic partnerships, and counselor support.
-
Bargaining Power of Suppliers (Moderate): Key suppliers provide NGS sequencers, reagents, and bioinformatics software. Illumina holds significant power as the primary platform provider. For specialized disposables (biopsy pipettes, culture media), there are multiple suppliers.
-
Bargaining Power of Buyers (Moderate to High): Buyers are IVF clinics and, indirectly, patients. Large fertility clinic chains have negotiating power on price. However, clinicians are often reluctant to switch PGT providers due to established workflows and trust in the lab's performance.
-
Threat of New Entrants (Moderate): Barriers are high due to specialized technical expertise in embryology and genetics, need for CLIA/CAP accreditation, complex bioinformatics, and the necessity of building trust with referring physicians. Startups often focus on novel bioinformatics or niPGT technology.
-
Threat of Substitutes (Low): Alternatives include prenatal diagnostic tests (CVS, amniocentesis), but these occur after pregnancy is established, leading to difficult decisions. Preimplantation testing is unique in its preventive nature. Non-genetic embryo selection methods (morphology) are inferior substitutes.
5. SWOT Analysis
-
Strengths: Addresses clear clinical needs (improved IVF success, prevention of genetic disease); strong clinical validation and improving reimbursement; continuous technological improvement (NGS); high patient demand in key demographics.
-
Weaknesses: High cost remains a barrier to universal adoption; ethical and regulatory controversies in some regions; requires highly skilled personnel (embryologists, geneticists); invasive biopsy procedure carries a small inherent risk to the embryo.
-
Opportunities: Expansion of indications (e.g., polygenic risk scoring for common diseases); development and validation of non-invasive PGT (niPGT); growth in emerging markets with rising ART adoption; integration of AI for embryo selection combined with genetics.
-
Threats: Stringent and variable international regulations; potential for payer pushback on cost-effectiveness for broad-based aneuploidy screening; public and ethical debates over "designer babies" and selection criteria.
6. Trend Analysis, Drivers & Challenges
Key Trends:
-
Routine Integration of PGT-A in IVF Cycles: Moving from a selective to a more standard offering, especially for patients over 35.
-
Shift to Comprehensive NGS Platforms: Replacing older FISH and array technologies with NGS for its superior resolution and ability to detect mosaicism and partial aneuploidies.
-
Rise of Non-Invasive PGT (niPGT): Analysis of cell-free DNA in spent embryo culture media. If widely validated, it could revolutionize the market by eliminating the embryo biopsy step.
-
Expansion of PGT-M Panels: Testing for a broader array of hereditary cancer syndromes and adult-onset conditions, raising ethical considerations.
Primary Drivers:
-
Increasing Maternal Age & Declining Fertility Rates: The primary demographic driver for PGT-A.
-
Advancements in Genomic Sequencing: NGS has made testing more comprehensive, accurate, and cost-effective.
-
Growing Awareness & De-stigmatization of IVF and Genetic Testing: Among prospective parents.
-
Improving Reimbursement Landscape: Gradual expansion of insurance coverage for PGT, particularly in the US for specific indications.
Critical Challenges:
-
High Out-of-Pocket Cost: Still a significant barrier for many patients, limiting market penetration.
-
Regulatory & Ethical Heterogeneity: Vastly different national laws regarding embryo selection, gender selection, and testing for late-onset conditions create a fragmented market.
-
Interpretation of Complex Results: Managing findings like mosaicism and variants of uncertain significance (VUS) poses clinical counseling challenges.
-
Need for Multidisciplinary Expertise: Requires seamless collaboration between REIs, embryologists, and genetic counselors.
7. Value Chain Analysis
-
Technology & Platform Development: Creating NGS instruments, assays, and bioinformatics pipelines (Illumina, Thermo Fisher).
-
Test Design & Assay Development: Designing probes and protocols for specific genetic conditions (PGT-M panels).
-
Sample Acquisition & Embryo Biopsy: Performed by skilled embryologists at the IVF clinic – the critical first physical step.
-
Genetic Analysis & Sequencing: DNA amplification, library prep, and NGS run at the reference lab.
-
Bioinformatics & Data Analysis: Interpreting raw sequence data to call chromosomal and single-gene variants.
-
Genetic Counseling & Reporting: Generating a clear clinical report and providing counseling to the physician/patient.
-
Clinical Decision & Embryo Transfer: The REI uses the report to select the embryo(s) for transfer.
Maximum value is captured by entities that control the end-to-end workflow from biopsy to final report and own the patient/physician relationship. This includes specialized labs with strong clinic partnerships and large fertility groups with captive lab services. The bioinformatics and data interpretation layer is a key source of proprietary value.
8. Quick Recommendations for Stakeholders
-
For PGT Laboratories (Natera, Reprogenetics, Igenomix): Invest in robust genetic counseling support to differentiate your service and help clinics manage complex results. Develop strong bioinformatics IP for accurate mosaic detection and data interpretation. Forge exclusive or preferred partnerships with large fertility clinic networks. Pioneer and validate niPGT to position for the next technology shift.
-
For IVF Clinics & Fertility Groups: Carefully select a PGT partner based on accuracy, support, and data integration capabilities, not just price. Invest in in-house embryologist training for consistent biopsy quality. Develop clear, ethical internal policies for handling complex results (mosaics, VUS). Consider vertical integration with a lab if volume justifies it.
-
For Technology Providers (Illumina, Thermo Fisher): Continue to drive down cost and simplify the workflow of NGS-based PGT to expand accessibility. Develop integrated, clinic-friendly software solutions for order entry, result reporting, and data management. Support research into new applications (e.g., polygenic risk scores) to expand the market.
-
For Patients & Advocacy Groups: Seek clinics that offer comprehensive genetic counseling. Understand the limitations, costs, and ethical dimensions of PGT. Advocate for expanded insurance coverage based on clinical outcomes data.
-
For Investors: Focus on companies with strong positions in the high-growth PGT-A segment and robust bioinformatics capabilities. Companies that are successfully integrating PGT into broader reproductive health platforms (e.g., combining with carrier screening, endometrial receptivity testing) are creating sticky, full-service models. Watch the niPGT space for potential disruptive entrants.
Report Basis: History Years: 2020-2024; Base Year: 2025; Forecast Period: 2026-2036.
Note: All market values (XX, YY) and CAGR (Z%) are illustrative placeholders. This analysis reflects the intersection of cutting-edge genomics, reproductive medicine, and evolving bioethics. Customized data, including indication-specific growth forecasts, pricing/reimbursement analysis, and detailed competitive landscape mapping, is available per client specifications.
Table of Contents
Global Preimplantation Genetic Diagnosis global market
1 Industry Overview of Preimplantation Genetic Diagnosis
1.1 Preimplantation Genetic Diagnosis Market Overview
1.1.1 Preimplantation Genetic Diagnosis Product Scope
1.1.2 Market Status and Outlook
1.2 Global Preimplantation Genetic Diagnosis Market Size and Analysis by Regions ()
1.2.1 United States
1.2.2 Europe
1.2.3 China
1.2.4 Japan
1.2.5 Southeast Asia
1.2.6 India
1.3 Preimplantation Genetic Diagnosis Market by Type
1.3.1 PGD for Aneuploidy Screening
1.3.2 PGD for Chromosomal Aberrations
1.3.3 PGD for Gender Selection
1.3.4 PGD for HLA Typing
1.3.5 PGD for Single Gene Disorder
1.3.6 PGD for X-linked diseases
1.4 Preimplantation Genetic Diagnosis Market by End Users/Application
1.4.1 Fertility Clinics
1.4.2 Health Care Facilities (including hospitals, diagnostic centers, and health care facilities)
1.4.3 Academic Institutes and Research Centers
2 Global Preimplantation Genetic Diagnosis Competition Analysis by Players
2.1 Preimplantation Genetic Diagnosis Market Size (Value) by Players ()
2.2 Competitive Status and Trend
2.2.1 Market Concentration Rate
2.2.2 Product/Service Differences
2.2.3 New Entrants
2.2.4 The Technology Trends in Future
3 Company (Top Players) Profiles
3.1 Genesis Genetics
3.1.1 Company Profile
3.1.2 Main Business/Business Overview
3.1.3 Products, Services and Solutions
3.1.4 Preimplantation Genetic Diagnosis Revenue (Million USD) ()
3.2 Genea Limited
3.2.1 Company Profile
3.2.2 Main Business/Business Overview
3.2.3 Products, Services and Solutions
3.2.4 Preimplantation Genetic Diagnosis Revenue (Million USD) ()
3.3 Illumina, Inc.
3.3.1 Company Profile
3.3.2 Main Business/Business Overview
3.3.3 Products, Services and Solutions
3.3.4 Preimplantation Genetic Diagnosis Revenue (Million USD) ()
3.4 Laboratory Corporation of America Holdings
3.4.1 Company Profile
3.4.2 Main Business/Business Overview
3.4.3 Products, Services and Solutions
3.4.4 Preimplantation Genetic Diagnosis Revenue (Million USD) ()
3.5 Natera, Inc.
3.5.1 Company Profile
3.5.2 Main Business/Business Overview
3.5.3 Products, Services and Solutions
3.5.4 Preimplantation Genetic Diagnosis Revenue (Million USD) ()
3.6 PerkinElmer, Inc
3.6.1 Company Profile
3.6.2 Main Business/Business Overview
3.6.3 Products, Services and Solutions
3.6.4 Preimplantation Genetic Diagnosis Revenue (Million USD) ()
3.7 Quest Diagnostics Incorporated
3.7.1 Company Profile
3.7.2 Main Business/Business Overview
3.7.3 Products, Services and Solutions
3.7.4 Preimplantation Genetic Diagnosis Revenue (Million USD) ()
3.8 Reprogenetics
3.8.1 Company Profile
3.8.2 Main Business/Business Overview
3.8.3 Products, Services and Solutions
3.8.4 Preimplantation Genetic Diagnosis Revenue (Million USD) ()
3.9 Reproductive Genetics Innovations LLC
3.9.1 Company Profile
3.9.2 Main Business/Business Overview
3.9.3 Products, Services and Solutions
3.9.4 Preimplantation Genetic Diagnosis Revenue (Million USD) ()
4 Global Preimplantation Genetic Diagnosis Market Size by Type and Application ()
4.1 Global Preimplantation Genetic Diagnosis Market Size by Type ()
4.2 Global Preimplantation Genetic Diagnosis Market Size by Application ()
4.3 Potential Application of Preimplantation Genetic Diagnosis in Future
4.4 Top Consumer/End Users of Preimplantation Genetic Diagnosis
5 United States Preimplantation Genetic Diagnosis Development Status and Outlook
5.1 United States Preimplantation Genetic Diagnosis Market Size ()
5.2 United States Preimplantation Genetic Diagnosis Market Size and Market Share by Players ()
5.3 United States Preimplantation Genetic Diagnosis Market Size by Application ()
6 Europe Preimplantation Genetic Diagnosis Development Status and Outlook
6.1 Europe Preimplantation Genetic Diagnosis Market Size ()
6.2 Europe Preimplantation Genetic Diagnosis Market Size and Market Share by Players ()
6.3 Europe Preimplantation Genetic Diagnosis Market Size by Application ()
7 China Preimplantation Genetic Diagnosis Development Status and Outlook
7.1 China Preimplantation Genetic Diagnosis Market Size ()
7.2 China Preimplantation Genetic Diagnosis Market Size and Market Share by Players ()
7.3 China Preimplantation Genetic Diagnosis Market Size by Application ()
8 Japan Preimplantation Genetic Diagnosis Development Status and Outlook
8.1 Japan Preimplantation Genetic Diagnosis Market Size ()
8.2 Japan Preimplantation Genetic Diagnosis Market Size and Market Share by Players ()
8.3 Japan Preimplantation Genetic Diagnosis Market Size by Application ()
9 Southeast Asia Preimplantation Genetic Diagnosis Development Status and Outlook
9.1 Southeast Asia Preimplantation Genetic Diagnosis Market Size ()
9.2 Southeast Asia Preimplantation Genetic Diagnosis Market Size and Market Share by Players ()
9.3 Southeast Asia Preimplantation Genetic Diagnosis Market Size by Application ()
10 India Preimplantation Genetic Diagnosis Development Status and Outlook
10.1 India Preimplantation Genetic Diagnosis Market Size ()
10.2 India Preimplantation Genetic Diagnosis Market Size and Market Share by Players ()
10.3 India Preimplantation Genetic Diagnosis Market Size by Application ()
11 Market Forecast by Regions, Type and Application ()
11.1 Global Preimplantation Genetic Diagnosis Market Size (Value) by Regions ()
11.1.1 United States Preimplantation Genetic Diagnosis Revenue and Growth Rate ()
11.1.2 Europe Preimplantation Genetic Diagnosis Revenue and Growth Rate ()
11.1.3 China Preimplantation Genetic Diagnosis Revenue and Growth Rate ()
11.1.4 Japan Preimplantation Genetic Diagnosis Revenue and Growth Rate ()
11.1.5 Southeast Asia Preimplantation Genetic Diagnosis Revenue and Growth Rate ()
11.1.6 India Preimplantation Genetic Diagnosis Revenue and Growth Rate ()
11.2 Global Preimplantation Genetic Diagnosis Market Size (Value) by Type ()
11.3 Global Preimplantation Genetic Diagnosis Market Size by Application ()
12 Preimplantation Genetic Diagnosis Market Dynamics
12.1 Preimplantation Genetic Diagnosis Market Opportunities
12.2 Preimplantation Genetic Diagnosis Challenge and Risk
12.2.1 Competition from Opponents
12.2.2 Downside Risks of Economy
12.3 Preimplantation Genetic Diagnosis Market Constraints and Threat
12.3.1 Threat from Substitute
12.3.2 Government Policy
12.3.3 Technology Risks
12.4 Preimplantation Genetic Diagnosis Market Driving Force
12.4.1 Growing Demand from Emerging Markets
12.4.2 Potential Application
13 Market Effect Factors Analysis
13.1 Technology Progress/Risk
13.1.1 Substitutes
13.1.2 Technology Progress in Related Industry
13.2 Consumer Needs Trend/Customer Preference
13.3 External Environmental Change
13.3.1 Economic Fluctuations
13.3.2 Other Risk Factors
14 Research Finding/Conclusion
15 Appendix
Methodology
Analyst Introduction
Data Source
List of Tables and Figures
Figure Global Preimplantation Genetic Diagnosis Market Size (Million USD) Status and Outlook ()
Table Global Preimplantation Genetic Diagnosis Revenue (Million USD) Comparison by Regions ()
Figure Global Preimplantation Genetic Diagnosis Market Share by Regions ()
Figure United States Preimplantation Genetic Diagnosis Market Size (Million USD) and Growth Rate by Regions ()
Figure Europe Preimplantation Genetic Diagnosis Market Size (Million USD) and Growth Rate by Regions ()
Figure China Preimplantation Genetic Diagnosis Market Size (Million USD) and Growth Rate by Regions ()
Figure Japan Preimplantation Genetic Diagnosis Market Size (Million USD) and Growth Rate by Regions ()
Figure Southeast Asia Preimplantation Genetic Diagnosis Market Size (Million USD) and Growth Rate by Regions ()
Figure India Preimplantation Genetic Diagnosis Market Size (Million USD) and Growth Rate by Regions ()
Table Global Preimplantation Genetic Diagnosis Revenue (Million USD) and Growth Rate (%) Comparison by Product ()
Figure Global Preimplantation Genetic Diagnosis Revenue Market Share by Type in 2017
Figure PGD for Aneuploidy Screening Market Size (Million USD) and Growth Rate ()
Figure PGD for Chromosomal Aberrations Market Size (Million USD) and Growth Rate ()
Figure PGD for Gender Selection Market Size (Million USD) and Growth Rate ()
Figure PGD for HLA Typing Market Size (Million USD) and Growth Rate ()
Figure PGD for Single Gene Disorder Market Size (Million USD) and Growth Rate ()
Figure PGD for X-linked diseases Market Size (Million USD) and Growth Rate ()
Figure Global Preimplantation Genetic Diagnosis Market Share by Application in 2017
Figure Preimplantation Genetic Diagnosis Market Size (Million USD) and Growth Rate in Fertility Clinics ()
Figure Preimplantation Genetic Diagnosis Market Size (Million USD) and Growth Rate in Health Care Facilities (including hospitals, diagnostic centers, and health care facilities) ()
Figure Preimplantation Genetic Diagnosis Market Size (Million USD) and Growth Rate in Academic Institutes and Research Centers ()
Table Preimplantation Genetic Diagnosis Market Size (Million USD) by Players ()
Figure Preimplantation Genetic Diagnosis Market Size Share by Players in 2013
Figure Preimplantation Genetic Diagnosis Market Size Share by Players in 2017
Table Genesis Genetics Basic Information List
Table Preimplantation Genetic Diagnosis Business Revenue (Million USD) of Genesis Genetics ()
Figure Genesis Genetics Preimplantation Genetic Diagnosis Business Revenue Market Share ()
Table Genea Limited Basic Information List
Table Preimplantation Genetic Diagnosis Business Revenue (Million USD) of Genea Limited ()
Figure Genea Limited Preimplantation Genetic Diagnosis Business Revenue Market Share ()
Table Illumina, Inc. Basic Information List
Table Preimplantation Genetic Diagnosis Business Revenue (Million USD) of Illumina, Inc. ()
Figure Illumina, Inc. Preimplantation Genetic Diagnosis Business Revenue Market Share ()
Table Laboratory Corporation of America Holdings Basic Information List
Table Preimplantation Genetic Diagnosis Business Revenue (Million USD) of Laboratory Corporation of America Holdings ()
Figure Laboratory Corporation of America Holdings Preimplantation Genetic Diagnosis Business Revenue Market Share ()
Table Natera, Inc. Basic Information List
Table Preimplantation Genetic Diagnosis Business Revenue (Million USD) of Natera, Inc. ()
Figure Natera, Inc. Preimplantation Genetic Diagnosis Business Revenue Market Share ()
Table PerkinElmer, Inc Basic Information List
Table Preimplantation Genetic Diagnosis Business Revenue (Million USD) of PerkinElmer, Inc ()
Figure PerkinElmer, Inc Preimplantation Genetic Diagnosis Business Revenue Market Share ()
Table Quest Diagnostics Incorporated Basic Information List
Table Preimplantation Genetic Diagnosis Business Revenue (Million USD) of Quest Diagnostics Incorporated ()
Figure Quest Diagnostics Incorporated Preimplantation Genetic Diagnosis Business Revenue Market Share ()
Table Reprogenetics Basic Information List
Table Preimplantation Genetic Diagnosis Business Revenue (Million USD) of Reprogenetics ()
Figure Reprogenetics Preimplantation Genetic Diagnosis Business Revenue Market Share ()
Table Reproductive Genetics Innovations LLC Basic Information List
Table Preimplantation Genetic Diagnosis Business Revenue (Million USD) of Reproductive Genetics Innovations LLC ()
Figure Reproductive Genetics Innovations LLC Preimplantation Genetic Diagnosis Business Revenue Market Share ()
Table Global Preimplantation Genetic Diagnosis Market Size (Million USD) by Product ()
Figure Global Preimplantation Genetic Diagnosis Revenue Market Share (%) by Product ()
Figure Global Preimplantation Genetic Diagnosis Market Share by Product in 2017
Table Global Preimplantation Genetic Diagnosis Market Size by Application ()
Figure Global Preimplantation Genetic Diagnosis Revenue Market Share (%) by Application in 2017
Table Top Consumer/End Users of Preimplantation Genetic Diagnosis
Figure United States Preimplantation Genetic Diagnosis Market Size (Million USD) and Growth Rate ()
Table United States Preimplantation Genetic Diagnosis Market Size (Million USD) by Players ()
Figure United States Preimplantation Genetic Diagnosis Market Size Share by Players in 2013
Figure United States Preimplantation Genetic Diagnosis Market Size Share by Players in 2017
Table United States Preimplantation Genetic Diagnosis Market Size by Application ()
Figure United States Preimplantation Genetic Diagnosis Revenue Market Share (%) by Application ()
Figure United States Preimplantation Genetic Diagnosis Market Size Share by Application in 2017
Figure Europe Preimplantation Genetic Diagnosis Market Size (Million USD) and Growth Rate ()
Table Europe Preimplantation Genetic Diagnosis Market Size (Million USD) by Players ()
Figure Europe Preimplantation Genetic Diagnosis Market Size Share by Players in 2013
Figure Europe Preimplantation Genetic Diagnosis Market Size Share by Players in 2017
Table Europe Preimplantation Genetic Diagnosis Market Size by Application ()
Figure Europe Preimplantation Genetic Diagnosis Revenue Market Share (%) by Application ()
Figure Europe Preimplantation Genetic Diagnosis Market Size Share by Application in 2017
Figure China Preimplantation Genetic Diagnosis Market Size (Million USD) and Growth Rate ()
Table China Preimplantation Genetic Diagnosis Market Size (Million USD) by Players ()
Figure China Preimplantation Genetic Diagnosis Market Size Share by Players in 2013
Figure China Preimplantation Genetic Diagnosis Market Size Share by Players in 2017
Table China Preimplantation Genetic Diagnosis Market Size by Application ()
Figure China Preimplantation Genetic Diagnosis Revenue Market Share (%) by Application ()
Figure China Preimplantation Genetic Diagnosis Market Size Share by Application in 2017
Figure Japan Preimplantation Genetic Diagnosis Market Size (Million USD) and Growth Rate ()
Table Japan Preimplantation Genetic Diagnosis Market Size (Million USD) by Players ()
Figure Japan Preimplantation Genetic Diagnosis Market Size Share by Players in 2013
Figure Japan Preimplantation Genetic Diagnosis Market Size Share by Players in 2017
Table Japan Preimplantation Genetic Diagnosis Market Size by Application ()
Figure Japan Preimplantation Genetic Diagnosis Revenue Market Share (%) by Application ()
Figure Japan Preimplantation Genetic Diagnosis Market Size Share by Application in 2017
Figure Southeast Asia Preimplantation Genetic Diagnosis Market Size (Million USD) and Growth Rate ()
Table Southeast Asia Preimplantation Genetic Diagnosis Market Size (Million USD) by Players ()
Figure Southeast Asia Preimplantation Genetic Diagnosis Market Size Share by Players in 2013
Figure Southeast Asia Preimplantation Genetic Diagnosis Market Size Share by Players in 2017
Table Southeast Asia Preimplantation Genetic Diagnosis Market Size by Application ()
Figure Southeast Asia Preimplantation Genetic Diagnosis Revenue Market Share (%) by Application ()
Figure Southeast Asia Preimplantation Genetic Diagnosis Market Size Share by Application in 2017
Figure India Preimplantation Genetic Diagnosis Market Size (Million USD) and Growth Rate ()
Table India Preimplantation Genetic Diagnosis Market Size (Million USD) by Players ()
Figure India Preimplantation Genetic Diagnosis Market Size Share by Players in 2013
Figure India Preimplantation Genetic Diagnosis Market Size Share by Players in 2017
Table India Preimplantation Genetic Diagnosis Market Size by Application ()
Figure India Preimplantation Genetic Diagnosis Revenue Market Share (%) by Application ()
Figure India Preimplantation Genetic Diagnosis Market Size Share by Application in 2017
Figure Global Preimplantation Genetic Diagnosis Market Size and Growth Rate ()
Table Global Preimplantation Genetic Diagnosis Market Size (Million USD) by Regions ()
Figure Global Preimplantation Genetic Diagnosis Market Size Share ()
Figure Global Preimplantation Genetic Diagnosis Market Size Share by Regions in 2025
Figure United States Preimplantation Genetic Diagnosis Revenue (Million USD) and Growth Rate ()
Figure Europe Preimplantation Genetic Diagnosis Revenue (Million USD) and Growth Rate ()
Figure China Preimplantation Genetic Diagnosis Revenue (Million USD) and Growth Rate ()
Figure Japan Preimplantation Genetic Diagnosis Revenue (Million USD) and Growth Rate ()
Figure Southeast Asia Preimplantation Genetic Diagnosis Revenue (Million USD) and Growth Rate ()
Figure India Preimplantation Genetic Diagnosis Revenue (Million USD) and Growth Rate ()
Table Global Preimplantation Genetic Diagnosis Market Size (Million USD) by Type ()
Figure Global Preimplantation Genetic Diagnosis Market Size Share by Type in 2018
Figure Global Preimplantation Genetic Diagnosis Market Size Share by Type in 2025
Table Global Preimplantation Genetic Diagnosis Market Size (Million USD) by Application ()
Figure Global Preimplantation Genetic Diagnosis Market Size (Million USD) by Application in 2018
1. Segments Analysis
By Test Type (Clinical Application):
-
PGT for Aneuploidy (PGT-A): The largest and fastest-growing segment. Screens embryos for chromosomal abnormalities (e.g., trisomy 21/Down syndrome) to improve IVF success rates and reduce miscarriage risk. Primarily driven by advanced maternal age and recurrent implantation failure.
-
PGT for Monogenic Disorders (PGT-M): Tests for specific inherited single-gene disorders (e.g., Cystic Fibrosis, Huntington's disease, BRCA-related cancers). A critical service for couples with known carrier status.
-
PGT for Structural Rearrangements (PGT-SR): For couples where one partner carries a balanced chromosomal rearrangement (e.g., translocation), to identify unbalanced embryos.
-
Emerging & Adjacent Applications: Includes PGT for HLA matching (to conceive a savior sibling) and non-invasive PGT (niPGT) using spent embryo culture media, which is in early-stage clinical adoption.
By Technology Platform:
-
Next-Generation Sequencing (NGS): The dominant and gold-standard platform for PGT-A and comprehensive chromosome screening. Offers high resolution, accuracy, and the ability to detect mosaicism.
-
Fluorescence In Situ Hybridization (FISH): A legacy technology for limited chromosome screening, now largely supplanted by NGS.
-
Comparative Genomic Hybridization (CGH) & Microarray-based Platforms (aCGH, SNP array): Bridge technologies between FISH and NGS, still in use but declining.
-
Polymerase Chain Reaction (PCR)-based Methods: Remain essential for PGT-M for specific single-gene disorder testing, often in conjunction with NGS.
By End-User:
-
Fertility Clinics & IVF Centers: The primary end-users, integrating PGT services into their patient treatment pathways. May have in-house labs or partner with specialized reference labs.
-
Specialized Genetics & Reference Laboratories: Centralized labs (e.g., Natera, Reprogenetics) that receive embryo biopsy samples from multiple clinics for analysis.
-
Academic & Research Institutions: Driving innovation in new PGT methodologies and expanding the scope of testable conditions.
By Service Model:
-
Standalone PGT Services: Offered by specialized labs to partnering IVF clinics.
-
Integrated IVF+PGT Programs: Offered by large fertility chains with their own lab capabilities.
2. Key Players
The market includes specialized reproductive genetics companies, large diagnostic labs, and sequencing technology providers.
Leading Companies:
-
Illumina, Inc. (Dominant provider of NGS platforms and associated PGT reagents/software via its reproductive health portfolio)
-
Thermo Fisher Scientific Inc. (Via its Applied Biosystems and genetic analysis solutions)
-
Agilent Technologies, Inc. (Microarray and NGS solutions)
-
PerkinElmer, Inc. (Via its reproductive health and genomics business)
-
CooperSurgical, Inc. (Integrated fertility company with PGT capabilities)
-
Natera, Inc. (Leader in cell-free DNA testing; strong in PGT via its Spectrum® platform)
-
Quest Diagnostics Incorporated
-
Laboratory Corporation of America Holdings (Labcorp)
-
Myriad Genetics, Inc. (Expertise in hereditary cancer and genetics)
-
Fujifilm Holdings Corporation (Via its Irvine Scientific subsidiary - media, consumables)
-
Vitrolife AB (Fertility media and consumables, expanding into genetics)
-
Progenesis, Inc. (Progeny) (Specialized PGT and genetics software)
-
Igenomix (Specialized reproductive genetics lab)
-
Reprogenetics (A leading PGT lab)
